{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-036740","form_type":"8-K","ticker":"TNXP","cik":"0001430306","company_name":"Tonix Pharmaceuticals Holding Corp.","filed_at":"2026-08-10T11:15:25+00:00","discovered_at":"2026-08-10T11:20:06.264637+00:00","generated_at":"2026-08-10T11:20:12.087206+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Tonix Q2 2026: TONMYA net sales $11M (+197% QoQ), net loss $40.6M","bullets":["TONMYA net sales ~$11M, up 197% QoQ; total net product revenue $13.5M vs $2.0M year ago.","Net loss $40.6M ($2.44/share) vs $28.3M ($3.86/share) in Q2 2025; cash $176.2M at June 30.","First patient enrolled in Phase 2 HORIZON study of TNX-102 SL for MDD; ~360 patients planned.","TNX-4800 Phase 2 Lyme prevention study on track to start Q1 2027 pending FDA agreement.","Sales force to expand to ~150 reps by September; payer coverage ~136M lives (43% U.S.)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-036740","json":"https://secwatch.observer/filing/0001493152-26-036740.json","markdown":"https://secwatch.observer/filing/0001493152-26-036740.md","text":"https://secwatch.observer/filing/0001493152-26-036740.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1430306/000149315226036740/0001493152-26-036740-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1430306/000149315226036740/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-10T11:20:12.087206+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}